Welcome to our dedicated page for Oncocyte Corporation news (Ticker: OCX), a resource for investors and traders seeking the latest updates and insights on Oncocyte Corporation stock.
Oncocyte Corp. (Nasdaq: OCX) is a diagnostics technology company focused on molecular tests for organ transplantation and oncology, and its news flow reflects this dual focus. Company updates frequently describe progress toward commercializing a dd-cfDNA-based transplant rejection monitoring test kit, including clinical trial milestones, regulatory interactions, and reimbursement developments. Oncocyte also reports on the use of its proprietary assays in peer-reviewed studies and collaborations with leading transplant centers and research institutions.
Investors and clinicians following OCX news can expect regular announcements about the GraftAssure transplant portfolio, which includes the GraftAssureCore lab-developed test, the GraftAssureIQ research-use-only kit, and the planned GraftAssureDx in-vitro diagnostic kit. Recent releases have highlighted Medicare reimbursement improvements for the company’s lab-developed transplant assay, expanded coverage for specific high-risk patient groups, and adoption of GraftAssure research kits by transplant centers in the United States, Europe, and Southeast Asia.
Oncocyte’s news also covers scientific publications that use its proprietary assays to study transplant biology, such as data in Transplantation Direct examining dd-cfDNA levels and kidney allograft biopsies. In oncology, updates have discussed the role of the DetermaIO gene expression test in studies like NeoTRIP in triple negative breast cancer, as well as the DetermaCNI blood-based monitoring tool.
In addition, OCX news items report on quarterly and annual financial results, pharma services revenue from its CLIA-certified Nashville lab, capital raises, and its strategic partnership with Bio-Rad Laboratories. Corporate communications may also include participation in healthcare and diagnostics conferences and plans related to corporate renaming. For those tracking the company, the news stream provides insight into clinical, regulatory, scientific, and capital markets developments affecting Oncocyte’s transplant and oncology diagnostics programs.
Oncocyte Corporation (Nasdaq: OCX) announced plans to present new clinical research data on DetermaIO™ at the ASCO Annual Meeting scheduled for June 3-7, 2022. The research evaluates the 27-gene IO score for predicting responses to immune checkpoint therapies in patients with metastatic colorectal, gastric, and breast cancers. Three abstracts will be presented throughout the meeting, highlighting the potential of DetermaIO in personalizing cancer treatments. The company will also support a CME event discussing advancements in molecular diagnostics.
Oncocyte Corporation (Nasdaq: OCX) announced a public offering of 26,266,417 shares of its common stock priced at $1.3325 each, along with warrants for 13,133,208.5 shares, expected to raise approximately $35 million before expenses. The offering is set to close by April 19, 2022. Funds will support commercialization of DetermaRx™, DetermaIO™, and TheraSure™, as well as collaboration with Life Technologies Corporation for regulatory approval of their tests. The underwriters have a 30-day option for additional shares to cover over-allotments.
Oncocyte Corporation (Nasdaq: OCX) has initiated an underwritten public offering of common stock and warrants, with plans to grant underwriters a 30-day option for an additional 15% of shares. The offering's completion is subject to market conditions. Proceeds will primarily support the commercialization of DetermaRx™, the development of DetermaIO™ and TheraSure™, and other tests in its pipeline, alongside costs from a collaboration with Life Technologies Corporation. A shelf registration statement was previously declared effective in June 2021.
Oncocyte Corporation (Nasdaq: OCX) announced a registered direct offering of 11,765 shares of Series A Convertible Preferred Stock, convertible into 7,689,542 shares of common stock at $1.53 per share. The offering aims to raise approximately $10 million in gross proceeds to enhance commercialization of DetermaRx™, DetermaIO™, and TheraSure™, among others. The Preferred Stock carries a 6% annual dividend and requires redemption by April 8, 2024 if not converted. There is no public trading market for the Preferred Stock.
Oncocyte Corporation (Nasdaq: OCX) announced findings from a real-world cohort study demonstrating that its DetermaIO test can effectively predict responses to immunotherapy in patients with bladder cancer. The study validated the test's capacity to identify responders to immune checkpoint inhibitors (ICIs) and confirmed previous results from the IMvigor210 trial. DetermaIO, launched in Q4 2021, assesses the tumor microenvironment, providing critical insights that could improve patient treatment decisions and outcomes. The findings were presented at the AACR Annual Meeting 2022.
Oncocyte Corporation (Nasdaq: OCX) announced it will present new data on its DetermaIO™ test at the AACR Annual Meeting 2022 from April 8-13 in New Orleans. The 27-gene expression test helps identify patients with bladder cancer who are likely to respond to immune checkpoint inhibitors (ICIs). This new analysis confirms previous findings linking the IO Score to responses to Genentech’s Tecentriq® therapy. DetermaIO is the first test to evaluate the entire tumor microenvironment, enhancing therapeutic decision-making for patients undergoing immunotherapy.
Oncocyte Corporation (Nasdaq: OCX) reported significant growth in its Q4 2021 results, with revenues up 104% year-over-year to $3.6 million and test volume increasing 54%. The company announced a strategic partnership with Thermo Fisher Scientific for distributed in vitro diagnostic assays. Notably, their DetermaCNI blood monitoring test has shown promising results for detecting cancer recurrence, and they are on track to launch the TheraSure Transplant Monitor in March 2022. Despite growing revenues, operating losses widened to $35.7 million in Q4 2021.
Oncocyte Corporation (Nasdaq: OCX) has announced the release of its financial and operating results for the fourth quarter and year ending December 31, 2021, set for March 10, 2022, post U.S. market close. A conference call will follow at 4:30 PM ET to discuss the results and corporate developments. Oncocyte specializes in precision diagnostics for cancer treatment, offering tests like DetermaRx™ and DetermaIO™ that aid in the diagnosis and monitoring of cancer. The company aims to enhance patient outcomes through its innovative diagnostics solutions.
Oncocyte Corporation (Nasdaq: OCX) announced participation in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference. Management will present during a fireside chat on February 15, 2022, at 4:30 PM EST. The conference aims to enhance patient outcomes through personalized diagnostic insights. Notably, Oncocyte offers proprietary tests like DetermaRx™ and DetermaIO™ to assist in cancer diagnosis and treatment. Investors can reach out to BTIG representatives for meeting opportunities, though the presentation won't be webcast.
Oncocyte Corporation (Nasdaq: OCX) announced a collaboration with Thermo Fisher Scientific to develop and co-market in vitro diagnostic (IVD) assays utilizing Thermo Fisher’s Ion Torrent Genexus System. The agreement includes clinical validation of the Oncomine Comprehensive Assay Plus for tumor profiling and development of Oncocyte’s DetermaIO™ test. The IVD assays aim to enhance precision medicine accessibility, potentially benefiting a significant portion of newly diagnosed cancer patients. The partnership leverages Thermo Fisher’s global capabilities to expand IVD availability beyond the U.S.